The latest market report published by Credence Research, Inc. “Radiodermatitis Market – Growth, Future Prospects, Competitive Analysis, 2017 – 2025,” the global radiodermatitis market was valued at US$ 295.5 Mn in 2016, and is expected to reach US$ 430.9 Mn by 2025 expanding at a CAGR of 4.18% from 2017 to 2025.
Browse the full report Radiodermatitis Market – Growth, Future Prospects, Competitive Analysis, 2017 – 2025 at https://www.credenceresearch.com/report/radiodermatitis-market
As per the report published in the European Oncology Nursing Socitey, 2016 as many as 95% of oncology patients opting radiation therapy will experience some degree of reaction on their skin due to radiation therapy. Currently no evidence supports of any medication present to prevent radiodermatitis. Some general guidelines have been considered for the effective management of radiodermatitis in oncology patients previously undergone radiation therapy such as gentle washing and drying, topical moisturizers should be applied before radiation therapy. Additionally usual hygiene practices must be followed such as use of mild detergent, deodorants not to be used on the exposed area, and smoking should be avoided.
In 2016, topical segment held the largest market share due to key drivers such as corticosteroids are considered as the gold standard for the treatment of radiodermatitis and the increasing demand for the hydrophilic creams which have been effective in overcoming the patients discomfort by providing moisture to the dry desquamation skin area. Dressings will be the fastest growing segment throughout the forecast period 2017-2025 majorly due to factors such as increasing oncology patients opting for radiation therapy, wide spectrum of dressings available as per the degree of skin complication due to radiation therapy. The technological advancement with the hydrocolloid and hydrogel dressings are finding tremendous applications as they are used for the management of moist desquamation in order to promote a moist environment to facilitate reepithelization.
In 2016, North America held the largest revenue share mainly due to factors such as rising prevalence of radiodermatitis, affordable reimbursement scenario and existence of developed research and healthcare institutions. Asia Pacific will be the fastest growing market throughout the forecast period 2017-2025, majorly due to factors such as rising prevalence of radiodermatitis, competitive market due to presence of existing and budding manufacturers involved in the palliative treatment of radiodermatitis, increasing disposable incomes in these regions and flourishing online market for the sale of medication for radiodermatitis treatment.
Key Market Movements:
- Rising demand for radiation therapy among the oncology patients
- Merger and acquisition between healthcare industries has resulted in the expansion of product portfolio for radiodermatitis treatment
- Supportive regulatory environment for radiodermatitis drugs
- Affordable reimbursement scenario for the treatment of radiodermatitis in developed countries